Bavarian Nordic A/S has secured a four-year contract with the UK Government to supply its MVA-BN vaccine against mpox and smallpox. Deliveries will be made on a scheduled basis, with optional flexibility provisions included in the agreement. The financial value was not disclosed. The UK Health Security Agency said maintaining access to appropriate vaccines is vital to protect the public from a range of infectious disease threats. MVA-BN, also known as Modified Vaccinia Ankara-Bavarian Nordic, is a non-replicating vaccine indicated for preventing mpox and smallpox and is approved in the U.S., Switzerland, Singapore, Mexico, Canada, the EU/EEA and the United Kingdom, under different brand names in some markets.